Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma

Summary

Patients with liver cirrhosis and hepatocellular carcinoma will undergo transarterial chemoembolisation (TACE) as clinically indicated and will be randomized to receive bevacizumab or placebo every 2 weeks up to 1 year. Tumor response will be assessed using MR of the liver and PET-scanning. It will be tested whether the addition of bevacizumab as angiogenic inhibitor will slow down tumor progression, reduce the need for re-embolisation and will improve patient survival.

Timeline

Start

2006-01

Primary completion

2009-12

Completion

2010-12

Outcome

Outcome not reported

Stopped: “Safety concerns in the treatment arm”

Drugs

Indications